Fosamax and Osteonecrosis of the Jaw: Examining the Scientific Evidence for Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Specific Exposure Concerns

The legacy of general health and science communication has long emphasized the importance of evidence-based understanding of therapeutic benefits and risks. In this tradition, large-scale randomized trials, such as the recent Japanese study of low-dose aspirin in older adults with cardiovascular risk factors, have shaped public and clinical perceptions of medication safety. These studies typically focus on common outcomes like cardiovascular events, but they also underscore the need for vigilance regarding rare but serious adverse effects that may emerge only after widespread use. This foundational perspective naturally extends to the domain of bone health medications, where bisphosphonates like Fosamax have been widely prescribed for osteoporosis. As with any pharmaceutical agent, the transition from general health awareness to specific exposure concerns requires careful consideration of risk profiles. In occupational settings, healthcare professionals and researchers may encounter patients or workers with prolonged Fosamax exposure histories, raising questions about potential associations with oral health complications. The bridge from general health literacy to occupational exposure concern lies in recognizing that medication safety data, while robust for common populations, may not fully capture risks in specific exposure contexts. This transition invites a focused examination of how cumulative Fosamax use might relate to conditions such as osteonecrosis of the jaw, without presuming mechanistic pathways, but rather acknowledging the need for systematic observation in exposed cohorts.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the need for systematic observation, we now turn to the specific relationship between Fosamax (alendronate sodium) and osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw. This condition is characterized by exposed, non-healing bone in the maxillofacial region, often presenting with pain, swelling, infection, and delayed healing after dental procedures. Diagnosis is based on clinical examination and imaging, with a key feature being the presence of necrotic bone that fails to heal despite appropriate care. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Evidence Linking Fosamax to ONJ

The scientific evidence connecting Fosamax to ONJ is supported by multiple lines of investigation. Pharmacologically, bisphosphonates like alendronate accumulate in bone tissue, particularly in areas of high bone turnover such as the jaw. This accumulation can suppress osteoclast activity, impairing normal bone remodeling and repair. Mechanistic pathways involve disruption of the delicate balance between bone resorption and formation. The jawbone's unique structure and high remodeling rate make it particularly susceptible to bisphosphonate-related complications. A multiscale characterization of jawbone treated with osteoporosis therapeutic agents, including alendronate, has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research, conducted in estrogen-deficient rat models, examined the effects of bisphosphonate (alendronate) on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). The findings contribute to understanding how bisphosphonate treatment alters jawbone physiology, potentially predisposing patients to ONJ.

Risk Factors and Warning Adequacy

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The adequacy of warnings about Fosamax and ONJ is addressed in the drug's prescribing information. The label explicitly states that osteonecrosis of the jaw has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It further notes that the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide guidance for healthcare providers and patients, though the label does not specify a precise timeline for risk reduction after discontinuation.

Causation Considerations and Timeline

Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and ONJ development. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, while a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its incidence in clinical trials was not significantly elevated compared to placebo, indicating that individual susceptibility and co-existing risk factors play important roles. The timeline between exposure and documented harm can vary widely. ONJ may develop months to years after initiating bisphosphonate therapy, with risk increasing with longer duration of use. The label notes that the risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, conservative debridement, infection control, and avoidance of further invasive dental procedures until healing occurs.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence connecting Fosamax to osteonecrosis of the jaw?

The scientific evidence includes pharmacological mechanisms where bisphosphonates like alendronate accumulate in jawbone, suppressing osteoclast activity and impairing bone remodeling. A multiscale characterization study in rat models (https://pubmed.ncbi.nlm.nih.gov/40345077/) showed altered jawbone properties. Additionally, the drug's label reports ONJ cases and notes increased risk with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ develop?

ONJ can develop months to years after initiating bisphosphonate therapy, with risk increasing with longer duration of use. The label notes that the risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.